From Financial Modeling Prep.: 2025-06-03 20:00:00

Venus Concept Inc. (NASDAQ:VERO) excels in capital utilization with a ROIC of 174.86%, higher than its 17.20% WACC. NeuroBo Pharmaceuticals struggles with a negative ROIC to WACC ratio, while Plus Therapeutics leads with a 263.26% ROIC and 44.18 ratio, showcasing superior efficiency. Investors should consider these metrics when evaluating these companies.



Read more at Financial Modeling Prep.:: Venus Concept Inc. (NASDAQ:VERO) Outshines Peers i…